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Prostate cancer (PCa) is a very heterogeneous disease, and there are constraints in its current diagnosis. Serum PSA levels, digital
rectal examination (DRE), and histopathologic analysis often drive to overdiagnosis and overtreatment. Since 2005, the presence of
the genetic rearrangement between transmembrane-serine protease gene (TMPRSS2) and the erythroblast transformation-specific
(ETS) member ERG (v-ets erythroblastosis virus E26 oncogene homolog avian) has been demonstrated in almost half of PCa cases.
Both FISH and RT-PCR are useful tools for detecting these rearrangements, but very few comparatives between both techniques
have been published. In this study, we included FFPE tumors from 294 PCa patients treated with radical prostatectomy with more
than 5 years of followup. We constructed a total of 20 tissue microarrays in order to perform break-apart and tricolor probe FISH
approaches that were compared with RT-PCR, showing a concordance of 80.6% (𝑃 < 0.001). The presence of TMPRSS2-ERG
rearrangement was observed in 56.6% of cases. No association between TMPRSS2-ERG status and clinicopathological parameters
nor biochemical progression and clinical progression free survival was found. In conclusion, this study demonstrates that both
FISH and RT-PCR are useful tools in the assessment of the TMPRSS2-ERG fusion gene status in PCa patients and that this genetic
feature per se lacks prognostic value.
1. Introduction
Prostate cancer (PCa) is a heterogeneous disease, which
ranges from indolent to lethal behaviour [1]. The diagno-
sis may be clinically suspect based on an elevated serum
prostate specific antigen (PSA) and/or abnormal digital rectal
examination (DRE), the definitive diagnosis established by
histopathologic examination of needle biopsy tissue. How-
ever, both PSA andDRE often lead to both overdiagnosis and
overtreatment presenting limitations when differentiating
between indolent and aggressive PCa [2]. In addition, biopsy
is also far from being optimal because it has demonstrated
a lack of sensitivity and high risk of morbidity for patients
[3]. Hence, in this context, there is an increasing demand
of specific biomarkers for PCa diagnosis that also provides
information regarding the prognosis of the disease.
In 2005 a novel set of fusion genes were described in
nearly half of the PCa cases [4] involving the 5󸀠-untranslated
region of TMPRSS2 (21q22) and the codifying region of
some transcription factors such as ERG (21q22), ETV1 (7p21),
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and ETV4 (17q21) among others [5]. To date, there are
10 different genes involved in these genetic fusions [6].
However, TMPRSS2-ERG is the most prevalent, and more
than 20 variants of the TMPRSS2-ERG fusion transcripts
have been described [6, 7], and the exon 1 of TMPRSS2
with the exon 4 or 5 of ERG (T1E4 or T1E5, resp.) are
the two most frequently involved variants [8]. The main
mechanisms by which the TMPRSS2-ERG fusion genes are
produced are interstitial deletion and balanced translocation
[9]. Because of their specificity, detection of these fusion
genes could be a valuable ancillary diagnostic tool in the early
detection of PCa [10]. In fact, these rearranged genes can be
detected either by fluorescence in situ hybridization (FISH),
reverse transcription polymerase chain reaction (RT-PCR)
techniques [7, 11–14], or branchedDNA (bDNA) analysis that
is a very sensitive approach [15].
FISH is considered the gold standard in the detection of
fusion rearrangements; the break-apart strategy is the main
approach used for this propose [12]. Yoshimoto et al. devel-
oped a three-colour assay able to distinguish between the two
mainmechanisms of gene rearrangement forTMPRSS2-ERG,
the interstitial deletion, or the reciprocal translocation [16].
In this sense, a commercial FISH assay comprising three-
color (tricolor) probes has been developed that are able to
discriminate between the putative fusion gene partners and
the different gene rearrangement mechanisms.
The aim of this study is to compare FISH and RT-PCR
techniques in the assessment of the TMPRSS2-ERG fusion
gene in a series of 294 cases of PCa and to establish the
prognostic usefulness of a commercial FISH tricolor deletion
probe.
2. Material and Methods
2.1. Case Selection. Formalin fixed and paraffin-embedded
(FFPE) blocks corresponding to PCa patients were retrieved
from the archives of the Biobank of the Fundacio´n Instituto
Valenciano de Oncolog´ıa according to the following criteria:
radical prostatectomy specimens and no history of previous
treatment for PCa (including androgen deprivation therapy
or chemotherapy prior to surgery). We obtained 294 PCa
specimens that met these criteria during the period between
1996 and 2008. All patients gave written informed consent,
and the study was approved by the Ethics Committee of
our institution (reference no. 2006-07). The clinical data
were reviewed from the clinical records and stored in a
PCa-specific database. The main characteristics and patient
demographics are shown in Table 1. In addition, we also
analyzed 20 samples of normal prostate tissue as controls
obtained from radical cystectomies neither of which was
benign prostatic hyperplasia or PCa. Haematoxylin and eosin
(H&E) stained slides were reviewed and Gleason pattern was
assigned.
2.2. TMAs Construction. We constructed 19 tissue microar-
rays (TMAs) comprising 294 tumor samples and another
TMA with 20 samples of normal prostatic tissue used as
control, containing three representative nonnecrotic cores of
Table 1: Demographics and main clinical and pathological features
of the analyzed series.
Parameters 𝑛 %
PSA
<10 ng/mL 186 63.3
10–20 ng/mL 66 22.4
>20 ng/mL 42 14.3
Gleason-sp
≤6 118 40.1
7 139 47.3
8–10 37 12.6
cT
≤cT2b 273 92.9
≥cT3a 19 6.5
pT
≤pT2 160 54.4
≥pT3 133 45.2
pN∗
pN0 190 64.6
pN ≥ 1 10 3.4
Perineural invasion
Negative 126 42.7
Positive 145 49.2
SP: specimen, cT: clinical stage, pT: pathological stage, PSA: prostatic-
specific antigen, and pN: pathologic stage with respect to lymph node status.
∗Lymphadenectomy was limited to the obturator fossa in most of the cases
at the inclusion period.
each case (1mm in diameter). TMAs were constructed using
a manual tissue arrayer (Beecher instruments, Silver Spring,
MD).
2.3. Fluorescence In Situ Hybridization (FISH). TMPRSS2-
ERG fusion status was determined by using both a break-
apart assay and a triple-labelled colour commercial probe
KBI-10726 (Poseidon, Kreatech Diagnostics, The Nether-
lands) flanking both TMPRSS2 and ERG. This probe is
designed to detect the deletion between TMPRSS2 and ERG
at 21q22 region but also translocations involving this region
with other genes such as ETV1 or ETV4.
For the break-apart assay we used two noncommercial
flanking probes (red (R) and green (G)) to ERG to detect rear-
rangements affecting this gene [5]. BAC clones covering both
distal and proximal regions of ERG on chromosomes 21q22,
CTD-2341018, and CTD-219A22, respectively, were obtained
from Children’s Hospital Oakland Research Institute (Oak-
land, CA, USA). The selection of these BAC clones was
performed using the genome browser from Centre de Reg-
ulacio´ Geno`mica, Barcelona, Spain (http://davinci.crg.es/).
BAC DNA isolation was performed according to Qiagen
Plasmid MIDI kit protocol (Qiagen Inc., Valencia, CA) and
was labelled using a nick translation kit (AbbottMolecular,
Abbott Park, IL). CTD-219A22 and CTD-2341018 BACs were
labelled with the Spectrum Red-dUTP (AbbottMolecular)
and Spectrum Green-dUTP (AbbottMolecular), respectively.
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The cytogenetic localization of all BACs was verified by
hybridization to normal metaphase spreads (G-banding with
inverted DAPI).
The FISH assay was carried out on 3 𝜇m thick FFPE tissue
sections. After deparaffinization, tissue sections were treated
with a commercial FFPE tissue section kit (MAD-FISH-PKII,
Master Diagnostica, Granada, Spain) following the manu-
facturer’s instructions. Briefly, the slides were immersed in
thiocyanate solution at 80∘C for 30 minutes and then treated
with a protease solution for 10 minutes at 37∘C. Afterwards,
the tissue sectionswere pretreated and probeswere denatured
at 80∘C for 5 minutes and hybridized overnight at 37∘C
using the hybridization System HyCrome (Euroclone S.pA.,
MI, Italy). Posthybridization washes were performed using a
posthybridization solution (MAD-FISH-PKII, Master Diag-
nostica, Granada, Spain) for 2 minutes at 72∘C and then,
the slides were counterstained with 7 𝜇L of 4, 6-diamino-2-
phenylindole (DAPI II, Vysis, Downers Grove, IL). Results
were visualized using a ZEISS, Imager.Z1 fluorescent micro-
scope with the AxioCam HRc camera the AxioVision 4
software (Carl ZEISS MicroImaging GmbH, Germany).
2.4. Criteria for the FISH Interpretation. The main mecha-
nisms of the TMPRSS2-ERG rearrangement are interstitial
deletion or translocation [17]. In our break-apart strategy, two
yellow (Y) or R and G adjacent signals indicate a normal
pattern, with no rearrangement in any of the two alleles.
Whereas one Y and one R or G signal alone or one Y signal
plus one R and one G separated signals indicate interstitial
deletion and translocation, respectively. Thirty-eight cases
of PCa were evaluated using break-apart probe in order to
compare this approach with tricolor probes (Figure 1).
The Poseidon TMPRSS2-ERG FISH (21q22) Del, Break,
TC (Kreatech Diagnostics, Netherlands) consists of three
probes: R, G, and blue (B). A nonrearranged case would show
a triplet of RGB signals; however, a translocated case would
be represented by one triplet signal corresponding to the
normal allele accompanied by another B and G fused and a
separated R signal. On the contrary, an interstitial deletion
would be shown by one fused triplet signal plus a B and R
fused signal. Another predominant pattern consisting of one
fused signal plus a B and G adjacent signal was also observed,
called the break pattern. Moreover, a fused RGB signal with
a separated B/G or R signal alone was assigned to unknown
rearrangement (Figure 1).
A total of 50 nuclei of each of the three cores per
case were counted. The cutoff was established using the 20
prostate tissue controls by counting 150 cells looking for the
translocation. After samples were evaluated, the average and
standard deviation of the nuclei with rearrangementwere cal-
culated.Then, a cutoff percentage was calculated as 3 positive
standard deviations of the average percentage of rearrange-
ment observed in normal tissues. Finally, this percentage was
established in 15% of cells showing an altered FISH pattern.
2.5. TMPRSS2-ERG Detection by RT-PCR. One representa-
tive FFPE block was identified from each case and three
sections of 20𝜇m thick were obtained for total RNA extrac-
tion.TheRNAquantification, RT-PCR, and the identification
of TMPRSS2-ERG fusion transcripts were carried out as
previously described in [18] (Figure 2).
PCR products of those TMPRSS2-ERG positive cases
were purified, quantified, and sequenced on an ABI3130xl
sequencer using the BigDye terminator v3.1 kit (Applied
Biosystems, Inc., Foster City, CA) with specific primers.
Sequencing Analysis v5.2 software (Applied Biosystems, Inc.,
Foster City, CA) and NCBI blast tool (http://www.ncbi
.nlm.nih.gov/BLAST/ were used to confirm the sequences
involved in the TMPRSS2-ERG fusions.
2.6. Performance Test. Considering FISH as gold standard,
the sensitivity, specificity, positive predictive values (PPV)
and negative predictive values (NPV) were calculated for RT-
PCR technique.
2.7. Statistical Analysis. Binary variables were used for the
statistical analysis reflecting the positivity status of the mea-
sures. The association between TMPRSS2-ERG and clinico-
pathological parameters (categorical) was assessed using a
chi-square test to determine homogeneity or linear trend
for ordinal variables. The significance level was established
at 5%. The impact of the biological factors on biochemical
(BPFS) and clinical progression free survival (PFS) was
analyzed by Log-rank tests. Biochemical progression was
defined as serum PSA level >0.4 ng/mL during followup,
whereas clinical progression was defined as local (prostatic
fossa), regional (lymph nodes), or distant (metastasis). Uni-
variate predictors of both BPFS and PFS were entered into
a Cox proportional hazards model using stepwise selection
to identify the independent predictors of poor outcome,
with a confidence interval (CI) of 95%. Statistical analysis
was carried out using the SPSS statistical software package
(version 15.0.1, SPSS Inc., Chicago, IL, USA).
3. Results
Since the three-color assay is a novel approach for TMPRSS2-
ERG analysis, a break-apart FISH was first conducted in
two TMAs including 38 cases in order to validate the
tricolor Kreatech probes. Both approaches presented good
concordance measured by chi-square test with a concordant
rate of 80.6%, a 13.8% false positive rate (FP), and 15.8% false
negative rate (𝑃 = 0.013) taking break-apart assay as the gold
standard.
For the whole series, using tricolor probes, 162 out
of the 294 PCa samples (55.1%) were positive for genetic
rearrangement. One hundred nineteen of these positive
cases (40.5%) showed a break-apart pattern and 35 (11.9%)
an interstitial deletion pattern. The remaining 8 (2.7%)
cases corresponded to undetermined fusion mechanisms.
The presence of TMPRSS2-ERG rearrangement or the type
of fusion mechanism assessed by means FISH showed no
correlation with any of the clinicopathological parameters
studied.Therewas only a trend towards statistical significance
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Undetermined rearrangement (1)
Undetermined rearrangement (2)
Undetermined rearrangement (3)Interstitial deletion
Balanced translocation
Normal
(A1)
(A2)
(A3)
(A4)
(A5)
(A6)
(a)
Normal
Balanced translocation
Interstitial deletion
(B1)
(B2)
(B3)
(b)
Figure 1: (a) Patterns obtained in the tricolor probe FISH analysis. Three fused signals indicate two normal alleles (A1); a balanced
translocation pattern is considered with a fused (RGB) signal and an adjacent BG with a separated R signals (A2); interstitial deletion
is indicated by a RGB signal and a B and R adjacent signals (A3); one RGB signal plus only one R, B, or G signal (A4, A5, A6, resp.)
corresponds to undetermined rearrangements. (b) Patterns of the dual color break-apart assay: normal pattern with two RG signals (B1);
balanced translocation is indicated by a RG signal plus a G and R separated signals (B2); one RG signal plus a R signal indicates interstitial
deletion (B3).
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Figure 2: Gel electrophoresis showing representative results for the
TMPRSS2-ERG gene status determined by RT-PCR. Lane 1: size
marker; lines 3, 4, 5, and 8: positive cases showing a PCR product
between the bands of 100 and 200 bp of the size marker; lanes 2, 6,
and 7 are negative cases, and lane 9 is a negative template control.
between the presence of perineural invasion and the fusion
gene detected by the tricolor FISH assay (𝑃 = 0.054)
(Table 2).
With the RT-PCR approach, 152 out of the 294 (51.7%)
showed expression of the TMPRSS2-ERG fusion gene. One
hundred and twenty-nine cases (43.9%) harbored the T1E4
variant (TMPRSS2 exon 1 fused to the exon 4 of ERG),
whereas 11 (3.7%) expressed the T1E5 variant. The identifi-
cation of fusion gene variant was not possible in two (0.7%)
cases.
Taking tricolor FISH as gold standard for determination
ofTMPRSS2-ERG, RT-PCR showed a sensitivity of 79.3% and
a specificity of 81.9%with a Positive PredictiveValue (PPV) of
80.9% and a Negative Predictive Value (NPV) of 80.2%. FISH
and RT-PCR assays showed concordant results in 237 out of
294 cases (80.6%, 𝑃 < 0.001) (Table 3).
Since FISH and RT-PCR showed a good agreement
in the assessment of TMPRSS2-ERG status, we considered
those cases as positive which presented the rearrangement
determined by any of the two procedures. The presence of
TMPRSS2-ERG according to this criterion showed no cor-
relation with any of the clinical and pathological parameters
(Table 4). However, and as aforementioned, there was a trend
towards the statistical significance between the presence of
TMPRSS2-ERG and perineural invasion (𝑃 = 0.091).
Regarding the prognostic implications of the presence
of gene fusion, Table 5 shows the results of both the uni-
variate and multivariate analyses of the clinicopathological
and molecular parameters for both BPFS and PFS. Neither
the TMPRSS2-ERG status nor the mechanisms of genetic
rearrangement were related to the clinical outcome in our
series (Figure 3).
4. Discussion
Currently, the standard diagnostic method for PCa is the
pathological evaluation of prostate biopsy in patients with
an elevated serum PSA level and/or an abnormal DRE.
However, this clinical approach lacks sufficient sensitivity [19]
being necessary for the discovery of new biomarkers that
can improve the accuracy of PCa diagnosis. The objective of
Table 2: Correlation between the mechanism of the rearrangement
and the clinical and pathological parameters.
Parameters TMPRSS2-ERGnegative (%)
Break
apart
(%)
Interstitial
deletion (%) 𝑃
PSA
<10 ng/mL 85 (47) 73 (73) 23 (23)
10–20 ng/mL 29 (45.3) 29 (45.3) 6 (9.4) 0.907
>20 ng/mL 18 (43.9) 17 (41.4) 6 (14.6)
Gleason-sp
2–6 56 (49.6) 45 (39.8) 12 (10.6)
7 57 (41.9) 61 (44.9) 18 (13.2) 0.693
>7 19 (51.4) 13 (35.1) 5 (13.5)
cT
≤cT2b 122 (45.9) 109 (41) 23 (23) 0.251
≥cT3a 9 (50) 9 (50) 0 (0)
pT
≤pT2 75 (48.7) 60 (39) 19 (12.3) 0.639
≥pT3 57 (43.5) 58 (44.3) 16 (12.2)
pN∗
pN0 84 (45.4) 75 (40.5) 26 (14.1) 0.177
pN ≥1 2 (20) 7 (70) 1 (10)
Perineural
invasion
Negative 63 (51.2) 44 (35.8) 16 (13) 0.054
Positive 53 (38.1) 70 (50.4) 16 (11.5)
Table 3: Crosstabs with the parameters of the comparison between
RT-PCR and FISH techniques.
Fish
𝑃
Negative Positive
RT-PCR
Negative 122 (80.2%) 27 (19%)
<0.001
Positive 30 (19.7%) 115 (81%)
this study was to assess whether TMPRSS2-ERG fusion gene
determined by tricolor FISH assay or RT-PCR could be used
as part of the diagnostic panel of PCa.
Several strategies can be employed when a FISH exper-
iment is designed. For instance, break-apart probes are
widely validated in numerous studies constituting a valuable
tool for determination of TMPRSS2-ERG in PCa [4, 20–
22]. However, this approach has its limitations. A positive
result indicates that ERG is rearranged, but a second deter-
mination of TMPRSS2 would be necessary to confirm the
presence of TMPRSS2-ERG because there are other genes
that could be rearranged with ERG such as NDRG1 and
SLC45A3 [23, 24]. With a tricolor strategy one determination
is enough to demonstrate the involvement of both genes.
Furthermore, although the break-apart FISH has been widely
used in investigation, this technique does not have diagnostic
approval because noncommercial homemade probes are
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Table 4: Correlation between the presence of TMPRSS2-ERG
determined by FISH and/or RT-PCR and the CPP.
Parameters TMPRSS2-ERGNegative (%)
TMPRSS2-ERG
Positive (%) 𝑃
PSA
<10 ng/mL 85 (64.4) 101 (62.3)
10–20 ng/mL 28 (21.2) 38 (23.5) 0.899
>20 ng/mL 19 (14.4) 23 (14.2)
Gleason-sp
2–6 50 (37.9) 68 (42)
7 61 (46.2) 78 (48.1) 0.292
>7 21 (15.9) 16 (9.9)
cT
≤cT2b 123 (93.2) 150 (93.8) 0.514
≥cT3a 9 (6.8) 10 (6.3)
pT
≤pT2 74 (56.1) 86 (53.4) 0.369
≥pT3 58 (43.9) 75 (46.6)
pN∗
pN0 82 (96.5) 108 (93.9) 0.317
pN ≥ 1 3 (3.5) 7 (6.1)
Perineural invasion
Negative 61 (51.7) 65 (42.8) 0.091
Positive 57 (48.3) 87 (53.3)
∗Lymphadenectomy was limited to the obturator fossa in most of the cases.
used.However, theKreatechPoseidonFISHprobes have been
developed specifically for their use in the clinical context
constituting a valuable ancillary test in the PCa diagnosis.
In the series herein presented, the FISH analysis showed
that 55.1% of PCa carried the TMPRSS2-ERG fusion gene
of which 40.5% showed a split signal pattern and 11.9%
evidenced an interstitial deletion. Remarkably, none of the
analyzed cases showed the balanced translocation pattern
consisting of one triplet signal (RGB) plus a B and G adjacent
signals with a separated R signal as indicated by the com-
mercial suppliers. However, the most frequent pattern was
a triplet fused signal plus a BG signal (the pattern so-called
break). This signal might correspond to a balanced translo-
cation in which the R signal is not visible. However, it is also
possible that the break pattern indicates an unknownmecha-
nism of rearrangement between TMPRSS2 and ERG. In eight
(2.7%) cases harboring the fusion gene, it was not possible to
determine the mechanism by which the rearrangement was
produced. Seven of these cases were scored asTMPRSS2-ERG
positive by RT-PCR, indicating a rearrangement between
both genes.The frequency of theTMPRSS2-ERG is consistent
with the series already published, ranging from 15% to 78%
[14, 17, 25, 26]. However, some differencesmight be explained
by variations in the cohorts under study, low number of cases
in some series, or sample selection bias [17, 25].
When referring to FISH, there are many questions asso-
ciated with the interpretation of the results, for instance,
the presence of multiple signals representing polyploidy or
multiple copies of TMPRSS2-ERG difficult to interpret [27];
the number of nuclei that should be counted; and, the score
of rearranged nuclei to be scored as positive [27, 28]. In our
series, we evaluated a median of 150 nuclei per case and
selected a 15% of rearranged nuclei as the optimum detection
for TMPRSS2-ERG, and that discriminates between PCa and
normal prostate tissue. This cutoff is similar to the one used
by Machado et al. in the determination of EWSR1 in Ewing
sarcoma by means of break-apart assay [27].
Unlike FISH, RT-PCR provides some advantages such as
lower cost of the procedure and its capacity of discriminating
different variants of the TMPRSS2-ERG fusion gene. In this
regard, some authors have shown an association between
some of these fusion subtypes with good [29] and poor
prognoses [30]. However, because of its high sensitivity and
cross-contamination, RT-PCR may on occasion give false
positive results. Hence, RT-PCR is an interesting and useful
technique in the diagnostic setting and should be considered
as potential complement to FISH.
To our knowledge, there is only one study comparing
FISH and RT-PCR in the determination of TMPRSS2-ERG
in PCa showing a concordance of 84.7% [21], very similar to
the herein reported. In the literature, there are other exam-
ples that compare FISH and RT-PCR in different settings
[27, 31, 32]: in breast cancer the comparison between both
techniques in the determination the HER2 status has shown
a good concordance ranging between 80–97% [33–35]; in the
case of dermatofibrosarcoma protuberans, this concordance
is of 67% for detection of COL1A1-PDGFB rearrangement
[28]; and finally, in Ewing Sarcomas, several studies showed
concordances between 55.5 and 100% [31, 36–38].
Regarding the association with clinical and pathological
parameters, no correlation between the rearrangementmech-
anisms and the surrogate prognostic parameters was found.
A trend towards statistical significance was observed between
the presence of TMPRSS2-ERG and a higher perineural
invasion, which is a surrogate parameter of poor prognosis,
although as an individual variable it loses its importance as a
prognostic value in most of multivariate analyses.
One important question to be addressed in this context
is the prognostic implications of the presence of fusion
gene in PCa samples. To date, it remains controversial, and
there are many studies defending the relationship between
TMPRSS2-ERG and both good [29, 39, 40] and poor [12,
17, 30, 41] prognoses. In addition, other many authors find
no correlation between the presence of TMPRSS2-ERG and
PCa outcome [42]. Interestingly, Attard et al. reported that
the presence of TMPRSS2-ERG resulted from an interstitial
deletion accompanied by a high copy number of this gene
(the so called class 2+ Edel), with a poor prognosis [12], but
to date, there are no studies confirming these observations.
A recent work of Tomlins et al. reported a prognostic panel
composed by TMPRSS2-ERG and PCA3 measured in urine
samples by means of transcription-mediated amplification
[43]. In addition, our group reported the different prognostic
panel in PCa that harbors the fusion gene indicating that
the determination of this biomarker would be useful in
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Figure 3: Kaplan-Meier plots of the univariate survival analysis. (a) Biochemical progression free survival (BPFS) according to theTMPRSS2-
ERG statusmeasured by FISH and/or RT-PCR. (b) BPFS according to themechanism of the rearrangement determined by tricolor FISH assay.
distinguishing groups of PCa patients defined by differential
prognostic indicators [18].
Despite the great number of studies published on this
matter, and due to differences with regard to the technology
used to determine TMPRSS2-ERG status and the heterogene-
ity of the cohorts, it is difficult to draw conclusions about
the prognostic involvement of this biomarker. Herein we
have analyzed a well-defined cohort with a long followup in
order to avoid these problems and no differences between the
TMPRSS2-ERG status and the genetic mechanisms by which
it has been produced with the prognosis of patients with PCa
have been found.
In summary, we have demonstrated the usefulness of a
commercial tricolor probe FISH approach for the identifica-
tion for theTMPRSS2-ERG status and the geneticmechanism
responsible of this fusion gene, as well as high grade of con-
cordance between this strategy and RT-PCR. Furthermore,
we have proved that the TMPRSS2-ERG status, although
specific for PCa, is not valid as a prognostic biomarker in PCa
patients treated with radical prostatectomy.
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